Literature DB >> 22246202

Targeting Aurora Kinase A enhances radiation sensitivity of atypical teratoid rhabdoid tumor cells.

Sujatha Venkataraman1, Irina Alimova, Tiffany Tello, Peter S Harris, Jeffrey A Knipstein, Andrew M Donson, Nicholas K Foreman, Arthur K Liu, Rajeev Vibhakar.   

Abstract

Atypical teratoid/rhabdoid tumors (ATRT) are rare, highly malignant, embryonal CNS tumors with a poor prognosis. Therapy relies on highly toxic chemotherapy and radiotherapy. To improve outcomes and decrease morbidity, more targeted therapy is required. Gene expression analysis revealed elevated expression of multiple kinases in ATRT tissues. Aurora Kinase A was one of the candidate kinases. The objective of this study was to evaluate the impact of Aurora Kinase A inhibition in ATRT cell lines. Our analysis revealed that inhibition of Aurora Kinase A induces cell death in ATRT cells and the small molecule inhibitor MLN 8237 sensitizes these cells to radiation. Furthermore, inhibition of Aurora Kinase A resulted in decreased activity of pro-proliferative signaling pathways. These data indicate that inhibition of Aurora Kinase A is a promising small molecule target for ATRT therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22246202      PMCID: PMC4681522          DOI: 10.1007/s11060-011-0795-y

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  25 in total

1.  Targeting tyrosine kinases in cancer: the second wave.

Authors:  Jose Baselga
Journal:  Science       Date:  2006-05-26       Impact factor: 47.728

2.  Inhibition of Aurora Kinase A enhances chemosensitivity of medulloblastoma cell lines.

Authors:  Ayman El-Sheikh; Rong Fan; Diane Birks; Andrew Donson; Nicholas K Foreman; Rajeev Vibhakar
Journal:  Pediatr Blood Cancer       Date:  2010-07-15       Impact factor: 3.167

3.  Alterations of the hSNF5/INI1 gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors.

Authors:  Jaclyn A Biegel; Lu Tan; Fan Zhang; Luanne Wainwright; Pierre Russo; Lucy B Rorke
Journal:  Clin Cancer Res       Date:  2002-11       Impact factor: 12.531

Review 4.  Atypical teratoid/rhabdoid tumors of the central nervous system.

Authors:  Alyssa T Reddy
Journal:  J Neurooncol       Date:  2005-12       Impact factor: 4.130

5.  Aurora A is a repressed effector target of the chromatin remodeling protein INI1/hSNF5 required for rhabdoid tumor cell survival.

Authors:  Seungjae Lee; Velasco Cimica; Nandini Ramachandra; David Zagzag; Ganjam V Kalpana
Journal:  Cancer Res       Date:  2011-04-26       Impact factor: 12.701

6.  Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry.

Authors:  Joanne M Hilden; Sharon Meerbaum; Peter Burger; Jonathan Finlay; Anna Janss; Bernd W Scheithauer; Andrew W Walter; Lucy B Rorke; Jaclyn A Biegel
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

7.  Amplification and overexpression of Aurora-A in esophageal squamous cell carcinoma.

Authors:  Shang-Bin Yang; Xiao-Bo Zhou; Hong-Xia Zhu; Lan-Ping Quan; Jin-Feng Bai; Jie He; Yan-Ning Gao; Shu-Jun Cheng; Ning-Zhi Xu
Journal:  Oncol Rep       Date:  2007-05       Impact factor: 3.906

Review 8.  Aurora kinase inhibitors.

Authors:  J J E M Kitzen; M J A de Jonge; J Verweij
Journal:  Crit Rev Oncol Hematol       Date:  2009-04-14       Impact factor: 6.312

9.  Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).

Authors:  John M Maris; Christopher L Morton; Richard Gorlick; E Anders Kolb; Richard Lock; Hernan Carol; Stephen T Keir; C Patrick Reynolds; Min H Kang; Jianrong Wu; Malcolm A Smith; Peter J Houghton
Journal:  Pediatr Blood Cancer       Date:  2010-07-15       Impact factor: 3.167

10.  Perimembrane Aurora-A expression is a significant prognostic factor in correlation with proliferative activity in non-small-cell lung cancer (NSCLC).

Authors:  Eiji Ogawa; Kazumasa Takenaka; Hiromichi Katakura; Masashi Adachi; Yosuke Otake; Yoshinobu Toda; Hirokazu Kotani; Toshiaki Manabe; Hiromi Wada; Fumihiro Tanaka
Journal:  Ann Surg Oncol       Date:  2007-11-28       Impact factor: 5.344

View more
  27 in total

Review 1.  Biology and Treatment of Rhabdoid Tumor.

Authors:  James I Geller; Jacquelyn J Roth; Jaclyn A Biegel
Journal:  Crit Rev Oncog       Date:  2015

2.  Long-term survival following additive radiotherapy in patients with atypical teratoid rhabdoid tumors.

Authors:  Khaled Elsayad; Jan Kriz; Laith Samhouri; Uwe Haverkamp; Ronald Straeter; Walter Stummer; Hans Theodor Eich
Journal:  Strahlenther Onkol       Date:  2016-06-07       Impact factor: 3.621

Review 3.  Atypical teratoid/rhabdoid tumors-current concepts, advances in biology, and potential future therapies.

Authors:  Michael C Frühwald; Jaclyn A Biegel; Franck Bourdeaut; Charles W M Roberts; Susan N Chi
Journal:  Neuro Oncol       Date:  2016-01-10       Impact factor: 12.300

4.  A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921).

Authors:  Yael P Mossé; Elizabeth Fox; David T Teachey; Joel M Reid; Stephanie L Safgren; Hernan Carol; Richard B Lock; Peter J Houghton; Malcolm A Smith; David Hall; Donald A Barkauskas; Mark Krailo; Stephan D Voss; Stacey L Berg; Susan M Blaney; Brenda J Weigel
Journal:  Clin Cancer Res       Date:  2019-02-18       Impact factor: 12.531

5.  Advancing biology-based therapeutic approaches for atypical teratoid rhabdoid tumors.

Authors:  Lindsey M Hoffman; Elizabeth Anne Richardson; Ben Ho; Ashley Margol; Alyssa Reddy; Lucie Lafay-Cousin; Susan Chi; Irene Slavc; Alexander Judkins; Martin Hasselblatt; Franck Bourdeaut; Michael C Frühwald; Rajeev Vibhakar; Eric Bouffet; Annie Huang
Journal:  Neuro Oncol       Date:  2020-07-07       Impact factor: 12.300

Review 6.  Molecular biology of pediatric brain tumors and impact on novel therapies.

Authors:  Lindsey M Hoffman; Ralph Salloum; Maryam Fouladi
Journal:  Curr Neurol Neurosci Rep       Date:  2015-04       Impact factor: 5.081

7.  Pediatric rhabdoid tumors of kidney and brain show many differences in gene expression but share dysregulation of cell cycle and epigenetic effector genes.

Authors:  Diane K Birks; Andrew M Donson; Purvi R Patel; Alexandra Sufit; Elizabeth M Algar; Christopher Dunham; B K Kleinschmidt-DeMasters; Michael H Handler; Rajeev Vibhakar; Nicholas K Foreman
Journal:  Pediatr Blood Cancer       Date:  2013-02-04       Impact factor: 3.167

8.  The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo.

Authors:  Ning Zhou; Kamini Singh; Maria C Mir; Yvonne Parker; Daniel Lindner; Robert Dreicer; Jeffrey A Ecsedy; Zhongfa Zhang; Bin T Teh; Alexandru Almasan; Donna E Hansel
Journal:  Clin Cancer Res       Date:  2013-02-12       Impact factor: 12.531

9.  SMARCB1 (INI-1)-deficient carcinomas of the sinonasal tract.

Authors:  Justin A Bishop; Cristina R Antonescu; William H Westra
Journal:  Am J Surg Pathol       Date:  2014-09       Impact factor: 6.394

Review 10.  Aurora A kinase (AURKA) in normal and pathological cell division.

Authors:  Anna S Nikonova; Igor Astsaturov; Ilya G Serebriiskii; Roland L Dunbrack; Erica A Golemis
Journal:  Cell Mol Life Sci       Date:  2012-08-03       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.